Abstract
Introduction Specific lipid-reducing therapeutics, including statins, are known for mitigating cardiovascular diseases due to their comprehensive benefits including anti-inflammatory properties, antioxidative stress response, and enhancement of endothelial function. The objective of our study was to determine the causative impact of lipid-reducing agents (HMGCR inhibitors, PCSK9 inhibitors, and NPC1L1 inhibitor) on the outcomes of pulmonary hypertension via a two-sample Mendelian randomization (MR) analysis.
Methods Two types of genetic tools were employed to estimate the exposure to lipid-lowering drugs, comprising expression quantitative trait loci of the drug’s target genes and genetic variations close to or within the target genes related to low-density lipoprotein (LDL cholesterol derived from a genome-wide association study). We utilized summary-data-based MR (SMR) and inverse-variance-weighted MR (IVWMR) methodologies for estimating effect sizes.
Results SMR analysis indicated that elevated HMGCR expression correlates with increased pulmonary hypertension risk (β=-0.964, se=0.276). Yet, no evident causative link between HMGCR-regulated LDL cholesterol and COVID-19 hospitalization was observed in the IVW-MR analysis (β = -0.21, se= 0.17).
Conclusions Our Mendelian randomization investigation unveiled a possible positive impact of lipid-lowering therapeutics on the prognosis of pulmonary hypertension. Importantly, no causal relation was established between LDL cholesterol and pulmonary hypertension.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the Traditional Chinese Medicine Inheritance and Innovation and "Qin Medicine" Development [No. 2021-03-22-001],Qin Chuangyuan Traditional Chinese Medicine Innovation Research and Development Transformation Project (No.2022-QCYZH-022),the Key Basic Natural Science Foundation of Shaanxi Province [No. 2022JZ-47], the Key Industrial Innovation Chain Project in Shaanxi Province of China [No. 2021ZDLSF02-03 and 2020ZDLSF01-08], the Key Program for the Shaanxi Provincial Health and Health Research Fund Project (No. 2022D024), and the Natural Science Foundation of Shaanxi Province [No. 2019JM-440 and No.2021JQ-911].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data used in our study is sourced entirely from the Opengwas website, which is a public, ethically-reviewed database. We did not collect data directly from any participants or subjects; thus, our study does not involve direct research or data collection on individuals. The data from the Opengwas website has already undergone appropriate ethical review and approval. Consequently, we believe that our study does not require separate ethical approval in this context.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data used in our study is sourced entirely from the Opengwas website, which is a public, ethically-reviewed database.